Skip to main content

What the FDA labels say about taking them together

Buprenorphine and lenacapavir

Lenacapavir's FDA label of August 27, 2026 names buprenorphine in its drug interactions section; the buprenorphine labels PlainMeds reads (4) do not name lenacapavir. The lenacapavir label: “Initiation of SUNLENCA in patients taking buprenorphine or methadone: A dose adjustment for buprenorphine or methadone may be needed. Monitor clinical signs and symptoms.”

Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the lenacapavir FDA label on DailyMed (effective August 27, 2026, Gilead Sciences, Inc.).

What does the buprenorphine label say about lenacapavir?

Buprenorphine's label (effective June 5, 2026) and its 3 other brand-application labels do not name lenacapavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed

What does the lenacapavir label say about buprenorphine?

Lenacapavir label, drug interactions

Initiation of SUNLENCA in patients taking buprenorphine or methadone: A dose adjustment for buprenorphine or methadone may be needed. Monitor clinical signs and symptoms.

Source: FDA drug label (Sunlenca), Gilead Sciences, Inc., effective August 27, 2026 (SPL set e5652804-29c4-40d7-aeb2-0142ed2a7b5b), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

27Buprenorphine generic labelers
0Lenacapavir generic labelers
BuprenorphineLenacapavir
Labeled forOpioid use disorder, PainHIV
Boxed warningNoNo
Pharmacy cost (NADAC)$0.277 per tablet 2 mg tablet sln/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?